These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32898246)

  • 61. Anticoagulation Reversal Strategies for Left Ventricular Assist Device Patients Presenting with Acute Intracranial Hemorrhage.
    Wong JK; Chen PC; Falvey J; Melvin AL; Lidder AK; Lowenstein LM; Miranpuri AS; Knight PA; Massey HT
    ASAIO J; 2016; 62(5):552-7. PubMed ID: 27347708
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy.
    Khorsand N; Veeger NJ; Muller M; Overdiek JW; Huisman W; van Hest RM; Meijer K
    Transfus Med; 2011 Apr; 21(2):116-23. PubMed ID: 21073580
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
    Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
    Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hemostatic assessment of combined anticoagulant therapy using warfarin and prothrombin complex concentrates in a case of severe protein C deficiency.
    Ogiwara K; Nogami K; Mizumachi K; Nakagawa T; Noda N; Ohga S; Shima M
    Int J Hematol; 2019 Jun; 109(6):650-656. PubMed ID: 30963470
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
    Majeed A; Meijer K; Larrazabal R; Arnberg F; Luijckx GJ; Roberts RS; Schulman S
    Thromb Haemost; 2014 Feb; 111(2):233-9. PubMed ID: 24154891
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage.
    Scott R; Kersten B; Basior J; Nadler M
    J Emerg Med; 2018 Jun; 54(6):861-866. PubMed ID: 29510892
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Four-factor prothrombin complex concentrate use for on-label versus off-label indications: a retrospective cohort study.
    Adkins BD; Shaim H; Abid A; Gonzalez A; DeAnda A; Yates SG
    J Thromb Thrombolysis; 2023 Jan; 55(1):74-82. PubMed ID: 35699871
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.
    Barton CA; Johnson NB; Case J; Warden B; Hughes D; Zimmerman J; Roberti G; McMillian WD; Schreiber M
    Am J Emerg Med; 2015 Nov; 33(11):1562-6. PubMed ID: 26143317
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage.
    Sarode R; Matevosyan K; Bhagat R; Rutherford C; Madden C; Beshay JE
    J Neurosurg; 2012 Mar; 116(3):491-7. PubMed ID: 22175718
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation.
    Riess HB; Meier-Hellmann A; Motsch J; Elias M; Kursten FW; Dempfle CE
    Thromb Res; 2007; 121(1):9-16. PubMed ID: 17407788
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety and effectiveness of a prothrombin complex concentrate in approved and off-label indications.
    Marcos-Jubilar M; García Erce JA; Martínez-Calle N; Páramo JA; Martínez Virto A; Quintana-Díaz M
    Transfus Med; 2019 Aug; 29(4):268-274. PubMed ID: 31347218
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use and effectiveness of a two-level initiation strategy for fixed-dose prothrombin complex concentrate according to the initial international normalized ratio in an emergency department in Japan.
    Suzuki K; Ikejiri K; Ishikura K; Imai H
    Acute Med Surg; 2021; 8(1):e669. PubMed ID: 34123389
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Emergency reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective multicenter two year French study from 2006 to 2008.
    Desmettre T; Dubart AE; Capellier G; Fanara B; Puyraveau M; Kepka S; Coquart J; Sheppard F; Tazarourte K
    Thromb Res; 2012 Sep; 130(3):e178-83. PubMed ID: 22726885
    [TBL] [Abstract][Full Text] [Related]  

  • 75. ACP Journal Club. 4F-PCC was noninferior to plasma in patients with acute major bleeding who needed urgent VKA reversal.
    Lang E
    Ann Intern Med; 2014 Apr; 160(8):JC6. PubMed ID: 24733223
    [No Abstract]   [Full Text] [Related]  

  • 76. Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis.
    Mohammadi K; Yaribash S; Sani MA; Talasaz AH
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):533-546. PubMed ID: 33864534
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: An observational analysis.
    Zheng Y; Tormey CA
    Transfus Med; 2020 Aug; 30(4):304-307. PubMed ID: 32342588
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects.
    Sørensen B; Johansen P; Nielsen GL; Sørensen JC; Ingerslev J
    Blood Coagul Fibrinolysis; 2003 Jul; 14(5):469-77. PubMed ID: 12851533
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.
    van Aart L; Eijkhout HW; Kamphuis JS; Dam M; Schattenkerk ME; Schouten TJ; Ploeger B; Strengers PF
    Thromb Res; 2006; 118(3):313-20. PubMed ID: 16182346
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
    Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
    Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.